In the pharmacy, the syringe is filled with AstraZeneca vaccine.
Christopher Neundorf | Image Alliance | Getty Images
The European drug regulator announced on Wednesday that the coronavirus vaccine developed by AstraZeneca and Oxford University may be linked to a rare blood clotting problem in adults receiving injections..
After reviewing all currently available evidence, it was found that some people who were vaccinated had unusual blood clots in rare cases.
In recent weeks, due to safety concerns, the Oxford-AstraZeneca shootings have been plagued the country. Several European countries temporarily suspended the use of their vaccines last month.
The European Medicines Agency (European Medicines Agency) said on March 31
The World Health Organization, the British Drug Regulatory Agency and the International Thrombosis and Hemostasis Association have all stated that the benefits of managing Oxford-AstraZeneca far outweigh the risks.
AstraZeneca has previously stated that its research did not find a higher risk of blood clots due to vaccination.
Since then, most countries/regions have resumed the use of injections, but many countries/regions have suspended vaccination for certain age groups.
According to reports, a senior official of the European drug regulatory agency said on Tuesday that there is a clear “link” between the Oxford-AstraZeneca vaccine and a very rare blood clot in the brain, although the direct cause is not yet known.
Marco Cavaleri, chairman of the EMA vaccine evaluation team, said in an interview with the Italian newspaper Il Messaggero published on Tuesday: “I think we can say that now, it is obviously related to the vaccine. However, we still don’t know what caused this reaction. .”
EMA subsequently denied in a statement to AFP that it had established any connection between the Oxford AstraZeneca shooting and the rare blood clot.
UK vaccine trials for children suspended
The Agency for Medicines and Healthcare Products Regulatory Agency, which approved the Oxford-AstraZeneca vaccine to be used in the UK, has been studying the data. Previously, there were a small number of reports of serious but rare blood clots in the UK and continental Europe. , Some of them have been fatal.
The UK trial of the Oxford-AstraZeneca vaccine for children has been suspended, and the drug regulatory agency has investigated possible links between injections and blood coagulation diseases, especially cases of intracerebral venous thrombosis, known as cerebral venous sinus thrombosis (CVST). ) And thrombocytopenia (low platelet content, which helps blood clot).
The British government pointed out that as of March 24 (inclusive), out of 18.1 million doses of AstraZeneca vaccine (two injections), there have been 22 reports of CVST and 8 other reports of low platelet thrombosis. Give before that date.
People wait at the vaccination center in Cologne, Germany on April 5, 2021.
Marius Becker | Image Alliance | Getty Images
Adam Finn, a professor of pediatrics at the University of Bristol in the United Kingdom, said: “We need to learn more about the people affected, we need to understand exactly how the disease occurs, and there are many other questions that remain unanswered at this time. “.
Finn said: “However, some things are very clear. The first is that these situations are really rare. Secondly, the vaccines that are available and in use in the UK are very effective in preventing COVID.”
In short, if you are currently being given a dose of Oxford-AstraZeneca vaccine, your chances of survival and recovery will increase if you continue to receive the vaccine, and your chances of survival will increase if you do not receive the vaccine Will decrease. “
— Holly Ellyatt of CNBC contributed to this report.